Your browser doesn't support javascript.
loading
A Rare Treatable Cause of Cardiomyopathy: Primary Carnitine Deficiency.
Basan, Hacer; Azak, Emine; Çetin, Ibrahim Ilker; Kiliç, Esra; Bilginer Gürbüz, Berrak; Özbey, Sümeyra Zeynep; Kasapkara, Çigdem Seher.
Afiliação
  • Basan H; Department of Pediatrics, Department of Pediatric Metabolic Diseases, Ankara City Hospital, Ankara, Turkey.
  • Azak E; Department of Pediatrics, Department of Pediatric Cardiology, Ankara City Hospital, Ankara, Turkey.
  • Çetin II; Department of Pediatrics, Department of Pediatric Cardiology, Ankara City Hospital, Ankara, Turkey.
  • Kiliç E; Department of Medical Genetics, Ankara City Hospital, Ankara, Turkey.
  • Bilginer Gürbüz B; Department of Pediatrics, Department of Pediatric Metabolic Diseases, Ankara City Hospital, Ankara, Turkey.
  • Özbey SZ; Department of Pediatrics, Department of Pediatric Metabolic Diseases, Ankara City Hospital, Ankara, Turkey.
  • Kasapkara ÇS; Department of Pediatrics, Department of Pediatric Metabolic Diseases, Ankara City Hospital, Ankara, Turkey.
Mol Syndromol ; 15(2): 156-160, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38585546
ABSTRACT

Introduction:

Primary carnitine deficiency (PCD) is a rare autosomal recessive disorder caused by loss of function mutations in the solute carrier family 22 member 5 (SLC22A5) gene that encodes a high-affinity sodium-ion-dependent organic cation transporter protein (OCTN2). Carnitine deficiency can result in acute metabolic decompensation or, in a more insidious presentation, cardiomyopathy. Cardiomyopathy associated with PCD often presents with life-threatening heart failure. This presentation also usually includes skeletal muscle myopathy. Early recognition of this disorder and treatment with carnitine can avoid life-threatening complications related to cardiomyopathy. Case Presentation Herein, we present a 10-month-old male patient with PCD, which was diagnosed while investigating the etiology of dilated cardiomyopathy and confirmed by molecular genetic analysis.

Conclusion:

Homozygous c.254_265 insGGCTCGCCACC (p.I89Gfs) pathogenic variant of the SLC22A5 gene was detected. With oral L-carnitine supplementation, the free carnitine level increased up to 14 µmol/L and the symptoms disappeared. LVEF increased by 45-70%. We would like to emphasize that this problem is a combination of the metabolic decompensation and the cardiac phenotypes, which are usually separated to either phenotype.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Mol Syndromol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Turquia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Mol Syndromol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Turquia